hERG Screening : Market Research Report

hERG Screening

Published: Jan. 1, 2008 - 147 Pages

I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
1. Introduction: hERG Screening; Normal Functioning of Heart; About the Heart; Electrocardiogram (EKG or ECG)
2.Global Market Analysis
3. Regional Market Analysis: North America; Major Companies in North America; ABR-Affinity BioReagents, Inc. (USA); Aurora Biomed, Inc. (Canada); AutoMate Scientific, Inc. (USA); AVIVA Biosciences Corporation (USA); Caliper Life Sciences, Inc.(USA); Cellular Dynamics International (USA); ChanTest Corporation (USA); Charles River Laboratories, Inc. (USA); CorDynamics (USA); Covance, Inc. (USA); Invitrogen, Inc. (USA); Lifespan Biosciences, Inc. (USA); MDS, Inc (Canada); Millipore Corporation (USA); Molecular Devices Corporation (USA); Neurion Pharmaceuticals, Inc. (USA); Novascreen Biosciences Corporation (USA); Novus Biologicals, Inc. (USA); Santa Cruz Biotechnology, Inc. (USA); Schrodinger, LLC (USA); Sigma-Aldrich Corporation (USA); Tocris Bioscience (USA); Wisconsin Alumni Research Foundation (WARF) (USA); Europe; Major Companies in Europe; Abcam PLC (UK); Astrazeneca PLC (UK); Aureus Pharma (France); bSys GmbH (Switzerland); Cambridge BioScience Ltd (UK); Cerep SA (France); ChemAxon Kft. (Hungary); CreaCell (France); Cyprotex plc (UK); Cytocentrics AG (Germany); Flyion GmbH (Germany); Nanion Technologies GmbH (Germany); Neurosolutions Ltd. (UK); RCC Ltd. (Switzerland); Sophion Bioscience A/S (Denmark); Asia-Pacific; Major Companies in Asia-Pacific; Abnova Corp. (Taiwan); RDDT (Australia); Strand Life Sciences (India); Synergia Life sciences (India); Tetra Q (Australia); WuXi PharmaTech Co.Ltd (China); Rest of World; More About the Patch Clamp Technique; Short QT Syndome; Long QT syndrome; Signs and symptoms; Causes; QT interval; PQRST wave; Types of LQTS; Genetical LQTS; Acquired LQTS; The Long QT syndrome and Torsade de pointes; Recording the Electrical Activity of Heart Beat; Diagnosis of LQTS; Treatment; Cell Lines; Qualified Cell Lines for Cell-Based ADME and Toxicity Evaluation
III. PRODUCT/TECHNOLOGY RESEARCH
1. Introduction: hERG Screening Growth Trends - Global Markets; Ion Channels; History; Basic Features of Ion Channel; Biological Role; The Patch Clamp Technique; Introduction; Methodology; Technique Configurations; The On-cell; The Inside out; The Whole-cell; The Outside out; The Perforated whole-cell; The Patch Clamp Technique Application; QPatch 16; QPatch HT; Q Patch Applications; QPATCH HT: Effective Application in Ion Channel Drug Discovery; Screening Station; Plates; Cell Preparation Unit; Liquid Handling System; Touch Screen; About Q Plate; The Q Plate Technique; Q Plate Prospects; Data Acquisition; Q Patch software; Types of Ion Channels; Voltage-gated Ion Channel; Structure; Mechanism; Ligand-gated Ion Channel; Introduction; Regulation; Clinical Relevance; Diversity of Ion Channels; Potassium Channels; Voltage-gated Potassium Channels; Diseases Related to Ion Channels; Ion Channel Genes of the Human Genome; Ion Channels as Drug Targets; Technologies for Ion Channel Characterization; Cell Lines; HEK 293 Cell Lines:; History; Application of HEK 293 Cells; CHO or Chinese Hamster Ovary Cells; hERG T-REx™ CHO Cells; Transfection; Calcium Phosphate Transfection; Normal Cardiac Cycle; Definition; Role of Potassium, Magnesium and Calcium in Normal Functioning of Heart; Magnesium; Calcium; Potassium; Membrane Potential; Improper Membrane Potential; Description; Task in Human Well being; Common Abnormalities and Ailments; Atrial Arrhythmias; Ventricular Arrhythmias; Cardiac Phase; Blood Pressure; Electrocardiogram (EKG or ECG):; History; QRS Complex:; T wave; Abnormality in Potassium Ion Channel:; Short QT Syndrome; Arrhythmia:; Torsades de Pointes : a cardiac arrhythmia; Characteristics of TdP; Causes of TdP; Risk factors for TdP; Treatment; QT Interval; Long QT Syndrome; LQTS - The Causes; LQTS - Risks; LQTS - Signs and Symptoms; Screening and Diagnostic Procedures; Complications; LQTS - Treatment; Medical Devices and Surgical Procedures; Clinical Trials; LQTS - The Types; Inherited Long QT syndrome; Genetic Basis and Treatment; Genetic Basis of LQTS; LQTS Associated Syndromes; Cofactors of Drug Induced LQTS:; Symptoms for Identification of Drug Induced LQTS; High probability of Drug Induced LQTS; Suspected Cases of Drug Induced LQTS; Unlikely Case of Drug Induced LQTS; Functioning of Heart; Drug Discovery Concerns; Action from Drug Approving Authorities; Role of hERG Blockers in Cardiac Disorders; The characteristics and Clinical Applications of Cardiac hERG/I (Kr) Potassium Channel; Cibenzoline an effective Na+-channel blocker; Biophysical Properties and Molecular Determinants of ziprasidone and its Role in; Block Opening hERG; In silico Modeling in hERG Channel Blockers; hERG Channel Archetypes and Pharmacophores; In silico Model Improvement and Assessment of HERG Binding; Testing In Silico for hERG K+ Channel Blockers; In Silico Categorization of hERG Channel Blockers: a Skill-Based Strategy; hERG Screening - Drugs Banned
2. Product Trends: The GLP hERG Channel Assay; Benefits Attributed to the Use of CDI Services; ICR 8000 - The latest Entrant in the Ion Channel Technology; Applications of ICR 800; Features and Parameters of ICR 800; Uses; ICR 12000; Features and Parameters of ICR 12000; Rubidium Flux Assay; IonWorks® HT in hERG Channel Screening; Measurement of hERG Channel Currents Using IonWorks HT System; Sophion’s Q Patch; QPatch 16; QPatch HT; Cell Lines in hERG Screening:
IV. MARKET DYNAMICS
1. Market Overview: Global Market Analysis
2. Major Companies in hERG Screening Industry: Abcam PLC (UK); Abnova Corp. (Taiwan); ABR-Affinity BioReagents, Inc. (USA); Astrazeneca PLC (UK); Aureus Pharma (France); Aurora Biomed, Inc. (Canada); AutoMate Scientific, Inc. (USA); AVIVA Biosciences Corporation (USA); bSys GmbH (Switzerland); Caliper Life Sciences, Inc. (USA); Cambridge BioScience Ltd (UK); Cellular Dynamics International (USA); Cerep SA (France); ChanTest Corporation (USA); Charles River Laboratories, Inc. (USA); ChemAxon Kft. (Hungary); CorDynamics (USA); Covance, Inc. (USA); CreaCell (France); Cyprotex plc (UK); Cytocentrics AG (Germany); Flyion GmbH (Germany); Invitrogen, Inc. (USA); Lifespan Biosciences, Inc. (USA); MDS, Inc (Canada); Millipore Corporation (USA); Molecular Devices Corporation (USA); Nanion Technologies GmbH (Germany); Neurion Pharmaceuticals, Inc. (USA); Neurosolutions Ltd. (UK); Novascreen Biosciences Corporation (USA); Novus Biologicals, Inc. (USA); RCC Ltd. (Switzerland); RDDT (Australia); Santa Cruz Biotechnology, Inc. (USA); Schrodinger, LLC (USA); Sigma-Aldrich Corporation (USA); Sophion Bioscience A/S (Denmark); Strand Life Sciences (India); Synergia Life sciences (India); Tetra Q (Australia); Tocris Bioscience (USA); Wisconsin Alumni Research Foundation (WARF) (USA); WuXi PharmaTech Co.Ltd (China)
3. Major Activities in hERG Screening Industry: Novel Cardiac Model Developed by PhysioStim to Investigate Compound Assays; Neuromed Licenses AurSCOPE Ion Channel Database from Aureus Pharma; PhysioStim Deploys the Innovative Cardiac Pharmacological System; TetraQ to Market NeuroSolutions’ Products in Australasia; Charles River Laboratories to Start a New Pre-Clinical Services Facility in Quebec; Charles River Laboratories Completes Joint Venture with Shanghai BioExplorer; Aureus Pharma Forms Alliance with MDL® Isentris®; Millipore Provides First L-type Calcium Channel for Drug Testing; Aureus Pharma Grants License to Bayer CropScience for its AurSCOPE Knowledge Databases; Cerep Extends Pharmaco-Informatics Alliance with Pfizer; Cerep Renews Agreement for 2007 with Eli Lilly; Covance Acquires Orbitrap™ to Become the First CRO with Latest Mass; Spectrometer Technology; AVIVA Biosciences Signs Distribution Agreement with Cosmo Bio Making Available its; Electrophysiology Service in Japan; Covance Granted License for B-CLEAR® to Predict In-vivo Liver Disposition; from In-vitro Assessments; Joint Venture Between Strand and BioIT Alliance; Sophion Bioscience Introduces New Revolutionary QPatch HT; Origenis Becomes First Customer to Aureus Pharma’s AurWEB; Aureus Pharma Signs License Agreement with Xention for AurSCOPE; Ion Channel Knowledge Database; Aureus Pharma Licenses Three Knowledge Databases to Siena Biotech S.p.A.; Joint Venture between TetraQ and VivoPharma for New Pre-Clinical; Drug Development Services; Serologicals Corporation Acquires Cytomyx; Aureus Pharma Launches AurWEB™ - The New Web Portal Solution for Knowledge; Driven Drug Discovery; Strand and Pharmidex to Jointly Develop New Silico Technology for CNS Drug Discovery; GlaxoSmithKline Granted License to Use Aureus Pharma’s Knowledge Databases; Strand Signs Agreement with ChemAxon to Develop New Software; Sophion Bioscience Initiates Joint Venture with Merck on QPatch HT; Sophion Enters Japanese Market; Bio-Rad Forms a Joint Venture with Aureus Pharma and Equbits LLC for In Silico Prediction of Biological Properties in Preclinical Drug Research; Aureus Pharma Extends Alliance with Sanofi-Aventis; Cyprotex Introduces New Innovative Screening Service; Sophion and Hydra Form One-of-a-Kind Reference Site for QPatch Automated; Patch Clamp System; Aureus Pharma Launches AurSCOPE® hERG Channel - The New Cardio; toxicity Related Database; Molecular Devices Launches New IonWorks® Quattro™ System for Accelerated; Ion Channel Screening
4. Regional Market Analysis
A. North America: Market Analysis
B. Europe: Market Analysis; Analysis by Geographic Region
C. Asia-Pacific: Market Analysis
D. Rest of World: Market Analysis
5. hERG Screening -The Industry Out Look
V. CORPORATE DIRECTORY

Abstract

This market insight report presents an in depth analysis of hERG Screening market. The study emphasizes on both the technology and product segments of hERG Screening in biotechnology and pharmaceutical application areas. The report provides essential information including market data, segmentation, market size, key trends, M&A, product developments, industry forecasts, corporate intelligence, and other relevant information. The report lists 128 companies that are engaged in hERG Screening services and/or production of hERG Screening tools/instruments. Projections and estimates are graphically represented by region. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific and Rest of World. The market is analyzed in US Dollars and includes 32 exclusive exhibits.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

hERG Screening

Table of Contents

Abstract